Navigation Links
Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split
Date:10/19/2009

DURHAM, N.C., Oct. 19 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) shareholders today voted to approve a 1-for-15 reverse stock split. The vote was part of a general meeting in which shareholders also voted to approve all of management's nominees to the company board of directors.

At the meeting, chairman and CEO Chris Stern also discussed plans for the formal launch of the company's Dermacyte(TM) Oxygen Concentrate Gel for the skin care market and discussed an expansion of the product development plan.

"The vote to approve the reverse stock split is the key component of our plan to move the listing of our stock from the over the counter bulletin board to a major exchange. We want to thank the shareholders who voted for this. We expect the reverse split will take effect in November. Shareholders will be getting more information about the details on this between now and then. In addition, we have initiated the process to move our listing to a major exchange. We will be working to facilitate and execute the listing move as fast as the stock exchange will allow us to do it," said Stern.

"It was great to be able to use today's meeting to talk about the launch of our first commercial product, Dermacyte Gel. It is now available for pre-order from the website BuyDermacyte.com and we expect to begin shipping product to fulfill orders in about four weeks. We have exciting plans for additional Dermacyte products and I expect this to begin generating revenues for the company."

The company also presented an updated product development plan which foresees a filing before the end of the year of an IND with the U.S. FDA for Oxycyte emulsion as a treatment for Carbon Monoxide poisoning.

Today' shareholder meeting was webcast live. A replay of the webcast may be found on the investor relations section of the company website. The replay will be archived for 90 days.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to plans to move the listing of the company's shares to a major exchange, timing of the shipment of Dermacyte Gel to customers and expectations of revenue from those sales, and plans to file an Investigational New Drug application with the FDA for Oxycyte emulsion as a treatment for Carbon Monoxide poisoning. There can be no assurance that those plans and expectations will be realized in the estimated time frame or at all. There be no assurance that Dermacyte or Dermacyte-related products will generate any revenue for the company nor that the FDA or any other government agency in any country will allow the company to initiate the contemplated clinical trials. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Oxygen Biotherapeutics, Inc.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ambulatory oxygen rarely a benefit in COPD patients without resting hypoxemia
2. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
3. Earths Oxygen May Have Arrived Earlier
4. San Diegos SeQual Technologies Loans 35 Portable Oxygen Units to Evacuees at Qualcomm Stadium
5. CQRC Statement on the NY Times Article on Medicares Home Oxygen Benefit
6. Statement from American Association for Homecare on New York Times Article about Home Oxygen Therapy
7. Link between chronic kidney disease and oxygen-deprived tissue
8. FOXO factor promotes survival of oxygen-deprived cancer cells
9. Infants with birthmarks received less oxygen in womb
10. OxySure(R) Systems, Inc. Named to 2008 Worlds Best Technologies (WBT) List For its Unique, Safe and Easy to Use Portable Emergency Oxygen Generator, Which Provides Medical Oxygen Without the Need for Compressed Tanks
11. Home Oxygen Care Leaders Say Presidents Budget Will Lead to Significant Patient Service Disruptions, Call for Thoughtful Reforms as Opposed to Repeated Cuts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Houston, TX (PRWEB) , ... February 27, 2017 ... ... the 75,000 customer threshold mark last week. In addition, Discount Power's RCE (Residential ... Volterra Energy LLC in March 2014. The company had 800 customers and 2,250 ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim Jong-nam, ... nerve agents and the deadly use of chemical weapons. Many questions exist about the ... small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, ...
(Date:2/26/2017)... ... 2017 , ... IndustryArchive.Org . is announcing a new way for B2B ... now only pay for B.A.N.T. quality sales leads based on the Sellers decision to ... new reality that B2B buyers are controlling the sales process via the Internet and ...
(Date:2/25/2017)... ... ... FCPX users now have the ability to sharpen a desired color range ... have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, and ... can visually see the color range effected with ease all within Final Cut ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis ... University of Pittsburgh points to eight genes that may explain why susceptibility to one ... the results of a study published today in the journal npj Schizophrenia. , ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... N.J. , Feb. 27, 2017  Interpace Diagnostics ... that provides clinically useful molecular diagnostic tests and pathology ... be presented at the upcoming United States ... being held March 4-10, 2017 in San ... reflect a review of data from the Company,s extensive ...
(Date:2/27/2017)... , Feb. 27, 2017  International Biophysics Corporation, a ... , today announced a 34% revenue growth in 2016 ... increase in unit sales.  This growth was fueled by its ... in addition to the expansion of its global sales of ... International Biophysics, CEO, "As we enter our 25 th ...
(Date:2/27/2017)... Calif. , Feb. 27, 2017   Vitasome ... line of nutritional supplements using its groundbreaking new liposome ... 90 percent of potency through digestion per Physician,s ... supplements solve the problem of nutritional waste and are ... degradation during digestive processes Improve bioavailability ...
Breaking Medicine Technology: